Damian A. Visser

Damian A. Visser

Auto-generated profile, based on publicly available information

Damian A. Visser

Research Institute for Medical Innovation, Radboudumc, Nijmegen, the Netherlands

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2019 in Cognitive Therapy and Research
Verified
Journal Article
Open access
PDF file
DVDamian A. Visser
Damian A. Visser
ITIndira Tendolkar
Indira Tendolkar
ASAart H. Schene
Aart H. Schene
LKLivia van de Kraats
Livia van de Kraats
HRHenricus G. Ruhe
Henricus G. Ruhe
JVJanna N. Vrijsen
Janna N. Vrijsen
Memory bias modification (MBM) is a relatively new approach at targeting biased processing—a central cognitive factor causing and maintaining depression. In this pilot study we aimed to develop a smartphone-based autobiographical memory training, a novel form of MBM. A total of 153 unselected participants were randomly allocated to one of three experimental training conditions (positive, negative or sham memory training) conducted over a period of three days. Autobiographical memory bias and depressive scores were assessed pre- and post-training, whilst recent event recall and explicit self-referent memory bias were assessed post-training. Positive memory bias significantly increased in the positive training condition, however memory bias did not significantly differ post-training between the three conditions. Participants who received positive training recalled a positive autobiographical event more frequently compared to the other conditions. No significant difference between conditions was found in the other outcomes, including symptoms. The novel smartphone-based MBM intervention seems apt to affect autobiographical memory of emotional material. Future research should explore its possible (therapeutic) application.

14 August 2019 in Laboratory Animals
Verified
Journal Article
Closed access
CLCathalijn Leenaars
Cathalijn Leenaars
RVRob Bm De Vries
Rob Bm De Vries
AHAnna Heming
Anna Heming
DVDamian Visser
Damian Visser
DHDavid Holthaus
David Holthaus
MRMerel Ritskes-Hoitinga
Merel Ritskes-Hoitinga
Animal models for cystic fibrosis (CF) have enhanced our understanding of the pathology and contributed to the development of new treatments. In the field of CF, many animal models have been developed and described. To our knowledge, thus far, none of the reviews of CF animal models has used a systematic methodology. A systematic approach to creating model overviews can lead to an objective, evidence-based choice of an animal model for new research questions. We searched Pubmed and Embase for the currently available animal models for CF. Two independent reviewers screened the results. We included all primary studies describing an animal model for CF. After duplicate removal, 12,304 publications were left. Because of the large number of models, in the current paper, only the genetic models are presented. A total of 636 publications were identified describing genetic animal models for CF in mice, pigs, ferrets, rats and zebrafish. Most of these models have an altered Cftr gene. An overview of basic model characteristics and outcome measures for these genetic models is provided, together with advice on using these data. As far as the authors are aware, this is one of the largest systematic mapping reviews on genetic animal models for CF. It can aid in selecting a suitable model and outcome measures. In general, the reporting quality of the included publications was poor. Further systematic reviews are warranted to determine the quality and translational value of these models further.

20 March 2025 in BJPsych Open
Verified
Journal Article
Open access
PDF file
DVDamian A. Visser
Damian A. Visser
DEDaphne S. Everaerd
Daphne S. Everaerd
HEHannah Ellerbroek
Hannah Ellerbroek
JZJanneke R. Zinkstok
Janneke R. Zinkstok
ITIndira Tendolkar
Indira Tendolkar
ASArnt F. A Schellekens
Arnt F. A Schellekens
Background: The COVID-19 pandemic and lockdowns had a significant impact on mental well-being and (mental) healthcare systems globally. Aims: To describe trends and dynamics of out-patient prescribing of psychotropic medications during the COVID-19 pandemic in The Netherlands. Method: Dispensed psychotropic medication prescriptions during the COVID-19 pandemic from March 2020 to March 2022 were retrieved from national registry data. Numbers of total and incident dispensed prescriptions and defined daily doses (DDDs) were identified for six medication groups. Overall pandemic-related changes in prescribing trends were analysed using interrupted time-series analyses. Lockdown-related prescribing dynamics were described using monthly risk ratios. Results: No overall pandemic-related changes in prescribing were detected, except for alcohol addiction medication, for which a pre-pandemic decline in total dispensed prescriptions and DDDs levelled off during the pandemic: +10 prescriptions per week (95% CI 7–11, P ≤ 0.001) and +111 DDDs per week (95% CI 56–165, P = 0.001). Monthly prescribing dynamics showed transient increases in all medication groups during the second and third lockdown periods. There were decreases in dispensed incident antidepressant and opioid addiction medication prescriptions during the first lockdown (average risk ratios: 0.87 and 0.88 respectively), and DDDs of dispensed incident and total attention-deficit hyperactivity disorder medication prescriptions and incident benzodiazepine prescriptions were elevated from the end of the second lockdown (average risk ratios: 1.40, 1.12 and 1.17, respectively). Conclusions: These findings raise concerns regarding possible over- and under-prescribing during the pandemic. Further understanding of specific factors driving these changes is necessary to help prepare for future mental health(care) challenges.

3 August 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
HEHannah Ellerbroek
Hannah Ellerbroek
ASArnt F. A Schellekens
Arnt F. A Schellekens
GKGerard Kalkman
Gerard Kalkman
DVDamian A Visser
Damian A Visser
CKCornelis Kramers
Cornelis Kramers
EDEveline L A van Dorp
Eveline L A van Dorp
Objectives The COVID-19 pandemic and related lockdown measures disrupted global healthcare provision, including opioid prescribing. In North America, opioid sales declined while opioid-related deaths increased. In Europe, the effect of the pandemic on prescribing is not yet known. Given the ongoing increase in opioid-related harm and mortality, it is crucial to analyse the impact of the COVID-19 crisis and lockdown measures on opioid prescribing. Therefore, the objective of this study was to characterise opioid prescribing in the Netherlands during the COVID-19 pandemic. Design A nationwide register-based study characterising opioid prescribing using aggregated insurance reimbursement data. Setting Dutch healthcare during the first 2 years of the COVID lockdown. Participants The whole Dutch population. Primary and secondary outcome measures Comparing the number of opioid prescriptions during the pandemic with a prepandemic period using a risk ratio (RR), with separate analysis on the prescription type (first-time or repeat prescription), patients’ sex, age and socioeconomic status. We also explored lockdown effects. Results During the first lockdown, the total number of new opioid prescriptions and prescriptions to young patients (briefly) decreased (RR 0.88, 95% CI 0.88 to 0.89 and RR 0.73, 95% CI 0.70 to 0.75, respectively), but the overall number of opioid prescriptions remained stable throughout the pandemic compared with prepandemic. Women, older patients and patients living in lower socioeconomic areas received more opioids per capita, but the pandemic did not amplify these differences. Conclusions The pandemic appears to have had a limited impact on opioid prescribing in the Netherlands. Yet, chronic use of opioids remains an important public health issue.

25 September 2026 in Journal of Addiction Medicine
Verified
Journal Article
Open access
DVDamian A. Visser
Damian A. Visser
EPErik P. Paling
Erik P. Paling
DEDaphne S. Everaerd
Daphne S. Everaerd
NANens van Alfen
Nens van Alfen
JZJanneke R. Zinkstok
Janneke R. Zinkstok
ASArnt F. A Schellekens
Arnt F. A Schellekens
Objectives: Abstinence rates of benzodiazepine tapering in individuals with sedative, hypnotic, or anxiolytic use disorder (SHA‑UD) are approximately 50%. Continuous subcutaneous flumazenil infusion during tapering may increase success rates and shorten tapering regimens; however, data on safety and effectiveness remain limited. We therefore aimed to assess the safety, withdrawal symptoms, and abstinence rates associated with flumazenil‑assisted 3-day benzodiazepine tapering in individuals with SHA‑UD. Methods: This exploratory, single‑arm, open‑label pilot study included adult participants with SHA‑UD (n=31) who had experienced at least one previous unsuccessful professionally guided tapering attempt. Participants received a 6‑day continuous subcutaneous flumazenil infusion (4 mg/24 h), while benzodiazepines were fully tapered during the first 3 days. Outcomes included adverse events, interictal epileptiform discharges (IEDs) on EEG, withdrawal severity, anxiety, and abstinence rates at 3‑month follow‑up. Results: After a withdrawal seizure occurred in one of the first 4 participants, valproate prophylaxis was introduced; no further seizures were observed thereafter. IEDs were detected in 6 participants during or after flumazenil infusion. Supportive medication (eg, propranolol, promethazine) was required in 87% of participants to manage withdrawal symptoms. Withdrawal severity and anxiety increased during detoxification, peaking during the final days of flumazenil infusion ( P =0.023). Sixteen participants (52%) were confirmed abstinent at 3-month follow-up by self-report and urinalysis. Conclusions: These findings warrant further investigation of flumazenil-assisted benzodiazepine detoxification in individuals with SHA-UD. Controlled studies are needed to further establish its safety profile and comparative effectiveness.